Blair Lapointe

Dose Therapeutics, Inc. is an early-stage biotechnology company based in Dallas, TX. Dose Therapeutics focuses on providing solutions for unmet medical needs, with a particular focus on high-risk neuroblastoma, an aggressive and often deadly form of childhood cancer. The company's first development candidate uses the tagging of a protein for degradation to potentially provide a new treatment option for children suffering from neuroblastoma. The company was founded by Steven L. McKnight and Deepak Nijhawan.

Dose Therapeutics, Inc. is an early-stage biotechnology company based in Dallas, TX. Dose Therapeutics focuses on providing solutions for unmet medical needs, with a particular focus on high-risk neuroblastoma, an aggressive and often deadly form of childhood cancer. The company's first development candidate uses the tagging of a protein for degradation to potentially provide a new treatment option for children suffering from neuroblastoma. The company was founded by Steven L. McKnight and Deepak Nijhawan.

Dose Therapeutics, Inc. is an early-stage biotechnology company based in Dallas, TX. Dose Therapeutics focuses on providing solutions for unmet medical needs, with a particular focus on high-risk neuroblastoma, an aggressive and often deadly form of childhood cancer. The company's first development candidate uses the tagging of a protein for degradation to potentially provide a new treatment option for children suffering from neuroblastoma. The company was founded by Steven L. McKnight and Deepak Nijhawan.

Dose Therapeutics, Inc. is an early-stage biotechnology company based in Dallas, TX. Dose Therapeutics focuses on providing solutions for unmet medical needs, with a particular focus on high-risk neuroblastoma, an aggressive and often deadly form of childhood cancer. The company's first development candidate uses the tagging of a protein for degradation to potentially provide a new treatment option for children suffering from neuroblastoma. The company was founded by Steven L. McKnight and Deepak Nijhawan.

Dose Therapeutics, Inc. is an early-stage biotechnology company based in Dallas, TX. Dose Therapeutics focuses on providing solutions for unmet medical needs, with a particular focus on high-risk neuroblastoma, an aggressive and often deadly form of childhood cancer. The company's first development candidate uses the tagging of a protein for degradation to potentially provide a new treatment option for children suffering from neuroblastoma. The company was founded by Steven L. McKnight and Deepak Nijhawan.